期刊文献+

超声心动图对马凡氏综合征患者的右心室收缩功能的评价

Right ventricular systolic function assessed by echocardiography in patients with Marfan syndrome
下载PDF
导出
摘要 目的用超声心动图评价成年马凡氏综合征(Marfan syndrome,MFS)患者是否存在右心室收缩功能不全。方法41例MFS患者及43例正常对照者行M型、二维及组织多普勒超声心动图,记录三尖瓣环收缩期位移(tricuspid annular plane systolic excursion,TAPSE)、右心室面积缩小率(fractional area change,FAC)及组织多普勒三尖瓣环收缩速度(Sta)。结果MFS患者右心室收缩功能指标虽处于正常范围,但均低于正常对照[TAPSE:(21±2)mm vs.(26±1)mm,P<0.01;FAC:36%±2%vs.42%±3%,P<0.01;Sta:(12±0.3)cm/s vs.(16±0.9)cm/s,P<0.01]。结论MFS患者存在右心室收缩功能不全,提示MFS可能累及右心室心肌。 Objectives To investigate right ventricular systolic function in adult patients with Marfan syndrome (MFS) by echocardiography. Methods Of 41 patients with MFS and 43 controls, tricuspid annular plane systolic excursion (TAPSE), right ventricular fractional area change (FAC) and tricuspid annulus tissue-Doppler imaging (TDI) peak systolic velocities (Sta) were studied using M-mode, two-dimensional, and TDI echocardiography respectively. Results TAPSE, FAC and Sta were significantly reduced in MFS patients when compared with those in controls [TAPSE: (21± 2) mm vs. (26-+1) mm, P〈0.01; FAC: 36%±2% vs. 42%±3%, P〈0.01; Sta: (12±0.3) cm/s vs. (16±0.9) cm/s, P〈0.011, although they were within the normal range. Conclusions Right ventricular systolic dysfunction exists in patients with MFS, which indicates primary myocardial impairment.
出处 《岭南心血管病杂志》 2012年第4期384-386,397,共4页 South China Journal of Cardiovascular Diseases
关键词 马凡综合征 右心室收缩功能 超声心动图 Marfan syndrome fight ventricular systolic function echocardiography
  • 相关文献

参考文献18

  • 1RAMIREZA F, DIETZ H C. Marfan syndrome: from molecular pathogenesis to clinical treatment [J]. Curr Opin Genet Dev, 2007, 17(3) : 252-258.
  • 2CANADAS V, VILACOSTA I, BRUNA I. Marfan syndrome. Part 1: pathophysiology and diagnosis [J]. Nat Rev Cardiol, 2010, 7(5): 256-265.
  • 3CANADAS V, VILACOSTA I, BRUNA I. Marfan syndrome. Part 2: treatment and management of patients [J]. Nat Rev Cardiol, 2010, 7(5): 266-276.
  • 4DE BACKER J F, DEVOS D, SEGERS P, et al. Primary impairment of left ventricular function in Marfan syndrome [J ]. Int J Cardiol, 2006, 112(3): 353-358.
  • 5KIOTSEKOGLOU A, BAJPAI A, BIJNENS B H, et al. Early impairment of left ventrieular long-axis systolic function demonstrated by reduced atrioventrieular plane displacement in patients with Marfan syndrome[J]. Eur J of Echocardiogr, 2008, 9(5) : 605-613.
  • 6DEBACKER J. The expanding cardiovascular phenotype of Marfan syndrome [J]. Eur J of Echocardiogr, 2009, 10(2): 213-215.
  • 7DE PAEPE A, DEVEREUX R B, DIETZ H C, et al. Revised diagnostic criteria for the Marfan syndrome [J. Am J Med Genet, 1996, 62(4): 417-426.
  • 8LANG R M, BIERIG M, DEVEREUX R B, et al. Recommendations for chamber quantification [ J ]. J Am Soc Echocardiogr, 2005, 18(12): 1440-1463.
  • 9RUDSKI L G,LAI W W,AFILALO J,et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography,a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography [J]. J Am Soc Echocardiogr, 2010, 23(7) :685-713.
  • 10KIOTSEKOGLOU A, SUTHERLAND G R, MOGGRIDGE JC, et al. Impaired right ventricular systolic function demonstrated by reduced atrioventricular plane displacement in adults with Marfan syndrome[J]. Eur J of Echocardiogr, 2009, 10(2) : 295-302.

二级参考文献19

  • 1刘威.氯沙坦有望用于马凡氏综合征患者主动脉瘤的预防[J].中华医学杂志,2006,86(24):1670-1670. 被引量:1
  • 2JUDGE D P, DIETZ H C. Marian's syndrome[J]. Lancet, 2005, 366 (9501) : 1965-1976.
  • 3VISCONTI R P, BARTH J L, KEELEY F W, et al. Codistribution analysis of elastin and related fibrillar proteins in early vertebrate development[J]. Matrix Biol, 2003, 22(2) : 109-121.
  • 4ISOGAI Z, ONO R N, USHIRO S, et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibrilassociated protein [J ]. J Biol Chem, 2003, 278 (4) : 2750-2757.
  • 5NEPTUNE E R, FRISCHMEYER P A, ARKING D E, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome[J]. Nat Genet, 2003, 33 (3): 407-411.
  • 6LOEYS B L, CHEN I, NEPTUNE E R, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBRI or TGFBR2[J]. Nat Genet, 2005, 37 (3): 275-281.
  • 7NG C M, CHENG A, MYERS L A, et al. TGF-beta- dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome [J]. J Clin Invest, 2004,114 (11): 1596-1592.
  • 8HABASHI J P, JUDGE D P, HOLM T M, et al. Losartan, an ATI antagonist, prevents aortic aneurysm in a mouse model of Marian syndrome[J]. Science, 2006, 312 (5770): 117-121.
  • 9TIERNEY E S, FEINGOLD B, PRINTZ B F, et al. Betablocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome[J]. J Pediatr, 2007, 150 (1): 77-82.
  • 10YETMAN A T, BORNEMEIER R A, MCCRINDLE B W. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome[J]. Am JCardiol, 2005, 95 (9): 1125-1127.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部